LRRK2 and Parkinson disease: Our work demonstrates that treatment with DNL151 can rescue lysosomal defects stemming from reduced GCase activity and provides additional preclinical support for the idea that LRRK2 inhibition may normalize lysosomal dysfunction more broadly in PD and could provide benefit to others beyond pathogenic LRRK2 variant carriers.